ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3016

Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis

Elizabeth M.A. Hensor1,2, Paul McKeigue3, Philip G. Conaghan1,2, Maya H. Buch1,2, Jennifer H. Barrett2,4, Jackie L. Nam1,2, Marco Colombo5, Athina Spiliopoulou5,6, Felix Agakov6, Stephen Kelly7, Myles J. Lewis7, Costantino Pitzalis7, Paul Emery1,2, Ann W. Morgan1,2 and IACON Consortium & PEAC Consortium, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3Medical School, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, 4School of Medicine, University of Leeds, Leeds, United Kingdom, 5Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, 6Pharmatics Limited, Edinburgh, Edinburgh, United Kingdom, 7Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, Outcome measures, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The original Disease Activity Score (DAS) was derived from clinicians’ therapeutic decisions1, which may have been influenced by patient-subjective factors such as general health status and joint tenderness. Modern imaging allows accurate measurement of synovitis and provides an objective standard against which to derive an updated DAS. We aimed to identify alternative forms of the DAS28 that are more strongly associated with ultrasound (US) measures of synovial inflammation than existing definitions.

Methods: Patients were included from 2 observational early RA cohorts [Inflammatory Arthritis CONtinuum (IACON n=433) and Pathobiology of Early Arthritis Cohort (PEAC n=117)], and a clinical trial (IDEA n=89); all satisfied ACR 1987 and/or ACR/EULAR 2010 criteria for RA. Data were available at repeated time-points [weeks 0, 26, 52, 78, 104 (IACON); 0, 26 (PEAC); 0, 50, 78 (IDEA)]; US scan was within 1 week of clinical exam. In IACON and IDEA US grey scale and power Doppler scores (0-3) for bilateral wrists, knees, MCPs 2&3, PIPs 2&3 and MTPs 1-5 were combined into a global GSPD score with Rasch analysis. In PEAC global GSPD was GS+PD in bilateral MCPs 1-5. Using linear mixed models with random intercepts for within-patient clustering we modelled the association in each cohort between GSPD and: original 4-component (4C) DAS28CRP score, a 2-component (2C) score with weights for SJC28 (0.15) and lnCRP+1 (0.49) from an existing MRI-based equation2, and DAS28CRP components [SJC28, CRP or TJC28, SJC28, CRP, general health VAS (GH)]. We compared models using restricted maximum likelihood deviance. Multiple imputation addressed missing data. Analyses used R v3.2.5.

Results: Models included 843, 237 and 183 visits from IACON, IDEA and PEAC respectively. Using DAS28 scores, deviance differences favoured 2C-DAS28 for IACON (2C-4C: -31) and PEAC (-16) but original 4C-DAS28 in IDEA (8). Nevertheless, using individual components, in all 3 studies only SJC28 and CRP were associated with GSPD. Coefficients from models using individual components are presented in Table 1. Despite differences in joints measured and methods of creating GSPD, the ratio of coefficients in the 2C models (SJC:CRP) were consistent: IACON 2.2, IDEA 2.1, PEAC 2.5.

Conclusion: Using a more objective measure of synovial inflammation, US-derived GSPD, the subjective elements of the DAS28 equation (TJC28, GH) can potentially be removed without loss of association with underlying synovitis and their removal may even improve the association. A 2-component DAS28CRP would simplify clinical examination and reduce the likelihood of missing data in clinical studies. This has the potential to improve patient care by targeting escalation of therapy to those with synovitis. Additional modelling will determine optimal weights for a 2-component DAS28CRP.

  1. van der Heijde DM et al. J Rheumatol. 1993;20:579-81.
  2. Baker et al. Arthritis Rheum. 2014;66:794-802.
Covariate Coefficient (SE) for association with GSPD
IACON 4-component 2-component
sqrt(SJC28) 1.06 (0.13) 1.03 (0.10)
ln(CRP+1) 0.48 (0.13) 0.46 (0.12)
sqrt(TJC28) -0.02 (0.11)
GH VAS 0.00 (0.01)
IDEA 4-component 2-component
sqrt(SJC28) 0.84 (0.27) 1.18 (0.18)
ln(CRP+1) 0.52 (0.24) 0.57 (0.22)
sqrt(TJC28) 0.39 (0.22)
GH VAS 0.00 (0.01)
PEAC 4-component 2-component
sqrt(SJC28) 5.48 (1.00) 5.32 (0.68)
ln(CRP+1) 2.17 (0.66) 2.09 (0.65)
sqrt(TJC28) 0.17 (0.88)
GH VAS -0.02 (0.03)
Table 1: Associations between DAS28CRP components and GSPD in each cohort

Disclosure: E. M. A. Hensor, None; P. McKeigue, None; P. G. Conaghan, AbbVie, Flexion, Eli Lilly, Novartis, Pfizer Inc, Roche, 5,AbbVie, Novartis, Roche, 8; M. H. Buch, None; J. H. Barrett, None; J. L. Nam, None; M. Colombo, None; A. Spiliopoulou, None; F. Agakov, Pharmatics Limited, 4; S. Kelly, None; M. J. Lewis, None; C. Pitzalis, Abbot/Abbvie, Astellas, Astra-Zeneca/MedImmune, BMS, Celgene, Grunenthal, GSK, Janssen/JNJ, MSD, Pfizer, Sanofi, Roche/Genetech/Chugai, UCB, 2; P. Emery, None; A. W. Morgan, None.

To cite this abstract in AMA style:

Hensor EMA, McKeigue P, Conaghan PG, Buch MH, Barrett JH, Nam JL, Colombo M, Spiliopoulou A, Agakov F, Kelly S, Lewis MJ, Pitzalis C, Emery P, Morgan AW. Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/validity-of-a-2-component-disease-activity-score-for-accurate-assessment-of-synovitis-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/validity-of-a-2-component-disease-activity-score-for-accurate-assessment-of-synovitis-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology